Skip to content
Pain Advocacy Coalition

Pain Advocacy Coalition

#RiseUp

  • Home
    • About PAC
    • Pain Advocacy Coalition Initiative
    • PAC Online Resources
    • Contact
  • Prevalence of Pain
    • Obstacles and the Status Quo
  • PAC Platform
    • PAC Call 2 Action
    • Collaboration: A Paradigm Shift
    • The Doctrine
    • Philosophy, Tools, Platforms and Strategy
  • #RiseUp Blog
    • Email Regarding Proposed Updated 2022 CDC Guideline for Prescribing Opioids
  • PAC Online Resources

Tag: Patient Rights

Posted on July 23, 2021July 23, 2021

Email Regarding Proposed Updated 2022 CDC Guideline for Prescribing Opioids

Rescind the 2016 Center for Disease Control (CDC) Opioid Prescribing Guidelines as Failed Public Health Policy Transparency Where is the admission, accountability or transparency regarding the purposefully, knowingly manipulated and concealed CDC data utilized as a foundation for instituting highly flawed public health policy, ultimately leading to “clinical misapplication” of recommendations further harming patients being …

Continue reading "Email Regarding Proposed Updated 2022 CDC Guideline for Prescribing Opioids"

Thanks for sharing!

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
  • More
  • Click to share on Pocket (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Skype (Opens in new window)
Image Credit:Pixabay

PAC Blog Category

Follow PACRiseUp on Facebook!

Follow PACRiseUp on Facebook!

Pain Advocacy Coalition

© Pain Advocacy Coalition (2017- 2020)  All rights reserved. Content does not constitute a medical consultation or legal advice. Please see a certified medical professional for medical advice or consult an attorney for legal advice. Content reflects the personal opinion of each individual contributor based upon available information. Unauthorized use/ duplication of content without express and written permission from content author is strictly prohibited. Excerpts or links may be used provided full clear credit is given to Pain Advocacy Coalition authors by including appropriate citation and links to the original content.

Follow Us

  • Facebook
  • Twitter
  • YouTube

THE PDMP & ITS BRANDING OF PAIN PATIENTS

https://youtu.be/xYp1hGOI_2k

Caylee Cresta: CMS FINAL CALL: RULES ON 2019 CMS OPIOID PRESCRIBING

https://youtu.be/lGfQ1YJ4-TM

Pain Advocacy Coalition

This slideshow requires JavaScript.

#Jams4eAdvocacy

#RiseUP

https://youtu.be/lwgr_IMeEgA

Pain Advocacy Coalition

© Pain Advocacy Coalition (2017- 2020)  All rights reserved. Content does not constitute a medical consultation or legal advice. Please see a certified medical professional for medical advice or consult an attorney for legal advice. Content reflects the personal opinion of each individual contributor based upon available information. Unauthorized use/ duplication of content without express and written permission from content author is strictly prohibited. Excerpts or links may be used provided full clear credit is given to Pain Advocacy Coalition authors by including appropriate citation and links to the original content.

RSS JD Supra Law

  • Texas Legislature Poised to Expand Access to Medical Patients as Texas Dispensing Organization License Round Closes May 27, 2023
    Texas may soon dramatically expand its medical cannabis market and increase access to medical cannabis products to thousands of additional patients across the state. Currently, there are only three licensed “Dispensing Organizations” (i.e., vertically-integrated medical cannabis companies engaging in cultivation, manufacturing, and retailing activities) in Texas. But that will soon change.
    Foley Hoag LLP - Cannabis and the Law
  • Congressional Efforts to Combat New Street Drug Threat Earn Bipartisan AG Support May 26, 2023
    A bipartisan coalition of 39 AGs sent a letter to Congressional leaders urging the swift passage of the Combatting Illicit Xylazine Act, which would provide resources to fight the recent uptick in overdoses and deaths caused by use of the street drug.
    Cozen O'Connor
  • Antitrust & Competition Life Sciences Quarterly Update - Q1 2023 May 25, 2023
    Our prior updates covered how FTC enforcement activity largely proceeded “as usual” during 2022 in the life sciences industry, with large pharmaceutical players buying or licensing promising, but still risky, assets from clinical- or preclinical-stage companies. But recent enforcement activity indicates the FTC is prepared to move from rhetoric to action in the life sciences […]
    Goodwin

Follow PACRiseUp on Facebook

Follow PACRiseUp on Facebook

Follow PACRiseUp on Twitter

My Tweets
 

Loading Comments...